Bioheart, a biotechnology company focused on using cells derived from a patient's body for treatment of heart damage, priced its 1.1 million share offering at $5.25 on Tuesday, the midpoint of the revised range. The company had originally filed for an offering of 3.6 million shares at a range of $14-$16. The shares began trading on the NASDAQ on Tuesday under the ticker BHRT. Dawson James Securities was the sole underwriter on the deal.
